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Abstract 
Background: Stroke can occur after myocardial infarction (MI) in the absence of atrial 
fibrillation (AF).  
Objectives: To identify risk factors (excluding AF) for the occurrence of stroke and 
developing a calibrated and validated stroke risk score in MI patients with heart failure 
(HF) and/or systolic dysfunction.  
Methods: The datasets included in this pooling initiative are derived from four trials: 
CAPRICORN, OPTIMAAL, VALIANT, and EPHESUS (the latter used for external 
validation). A total of 22,904 patients without AF or oral anticoagulation were included 
in this analysis. The primary outcome was stroke and death was treated as a “competing 
risk”. 
Results: During a median follow-up of 1.9 (percentile25-75=1.3-2.7) years, 660 (2.9%) 
patients had a stroke. These patients were older, more often female, smokers, 
hypertensive, had higher Killip class, lower estimated glomerular filtration rate (eGFR), 
higher proportion of MI, HF, diabetes, and stroke histories. The final stroke risk model 
retained older age, Killip class 3 or 4, eGFR≤45ml/min/1.73m2, hypertension history, 
and previous stroke. The models were well calibrated and showed moderate/good 
discrimination (c-index =0.67). The observed 3-year event rates increased steeply for 
each sextile of the stroke risk score (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9%, 
respectively) and were in agreement with the expected event rates. 
Conclusion: Readily accessible risk factors associated with the occurrence of stroke 
were identified and incorporated in an “easy-to-use” risk score. This score may help in 
the identification of patients with MI and HF and a high risk for stroke despite not 
presenting AF. 
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Condensed abstract 
Stroke can occur after myocardial infarction (MI) in the absence of atrial fibrillation 
(AF). In a large (22,904) MI population with systolic dysfunction but without AF, 660 
(2.9%) patients had a stroke during a median follow-up of 1.9 years. The final stroke 
risk model retained older age, Killip class 3/4, eGFR≤45ml/min/1.73m2, hypertension, 
and previous stroke as independent stroke risk factors. The models were well calibrated 
and showed moderate/good discrimination (c-index=0.67). These readily accessible risk 
factors were incorporated in a risk score that may help in the identification of patients 
with a high risk for stroke despite not presenting AF. 
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eGFR, estimated glomerular filtration rate 
OAC, oral anticoagulant 
CRF, case report form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Introduction 
 Stroke may be potentially devastating for the patient and has important impact 
on their families, caregivers and society(1). Stroke can occur after myocardial infarction 
(MI) further complicating MI management and increasing associated death rates(2). The 
incidence rates of stroke after MI vary between ≈1% and 5%(3-6). The formation of 
areas of akinesia and/or dyskinesia in the left ventricle after MI may increase the risk 
for mural thrombi formation and subsequent peripheral thromboembolism and 
stroke(7). Nonetheless, these reports included patients with atrial fibrillation (AF) which 
is a major risk factor for stroke(8). Hence, whether is MI, akinesia, systolic dysfunction, 
heart failure (HF), AF or other factors that contribute to the occurrence of stroke in the 
post-MI setting is difficult to ascertain(9). Consequently, the risk of stroke in post-MI 
patients but without AF is poorly defined. 
 Myocardial infarction complicated with systolic dysfunction and/or HF (but 
without AF) may create a particularly thrombogenic environment per se, through 
fulfillment of the Virchow triad (stasis of blood flow, endothelial injury, and 
hypercoagulability)(10). Therefore, analyzing the incidence and risk factors for stroke in 
a “complicated” MI population without AF may help identify patients at high risk in 
whom an early intervention (e.g. oral anticoagulation) may be valuable for stroke 
prevention.  
 The high-risk MI initiate provides a unique opportunity to study the occurrence 
of stroke in patients with “complicated” MI but without AF in more than 20,000 
patients and 600 stroke events. The present study aims to identify the characteristics of 
the patients who had a stroke during follow-up stroke and to develop a calibrated and 
validated stroke risk score in this population.  
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Methods 
Study population 
The high-risk MI initiative consists of a previously published cohort of pooled 
patient data derived from four clinical trials(11). Briefly, the main objectives of the 
project are to provide a comprehensive and statistically robust analysis of long-term 
clinical outcomes in high-risk survivors of MI. The datasets included in this pooling 
initiative were: the effect of Carvedilol on Outcome after Myocardial Infarction in 
Patients with Left Ventricular Dysfunction trial (CAPRICORN)(12, 13), the Eplerenone 
Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study 
(EPHESUS)(14, 15), the Optimal Trial in Myocardial Infarction with Angiotensin II 
Antagonist Losartan (OPTIMAAL)(16, 17) and the Valsartan in Acute Myocardial 
Infarction trial (VALIANT)(18, 19). Full details of total enrolled patients, the inclusion 
and exclusion criteria for each trial, the endpoints as well as the results have previously 
been published(11). Each trial enrolled patients with left ventricular systolic 
dysfunction, HF or both between 12 h and 21 days after acute MI. The information 
included in this pooled database does not include the treatment randomization 
assignments for each trial. 
The respective chairpersons of the Steering Committees of the four trials 
initiated the pooling project.  
The studies were all conducted in accordance with the Declaration of Helsinki 
and approved by site ethics committees. All participants gave written informed consent 
to participate in the studies. 
For the present analysis, we selected patients without history of AF or AF 
present at randomization ECG or those treated with an OAC.  
Outcomes 
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The primary outcome was stroke. Stroke was consistently defined as a focal 
neurologic deficit lasting more than 24 hours or resulting in death that was presumed to 
be related to stroke. All-cause death was considered the competing-risk event.  
Endpoints were independently adjudicated in the respective trials. 
Statistical methods 
Continuous variables were expressed as mean ± standard deviation (SD) and 
categorical variables as frequencies and proportions. For comparison of means and 
proportions, student t-test and chi-square test were used, respectively. 
Time-to-event analysis was conducted using a competing-risk model as 
described by Fine and Gray(20), with stroke as outcome event and death as competing-
risk. Log-linearity was checked by testing the functional forms of the covariable by the 
Kolmogorov-type supremum test and by visual inspection by plotting the beta estimates 
versus the mean across deciles. Covariables were entered in the multivariable model in a 
stepwise regression analysis with p-value to enter and stay in the model set to p =0.15 
and p =0.05, respectively. Covariables considered to be of potential prognostic impact 
were age, gender, body mass index, smoking status, systolic blood pressure, heart rate, 
Killip class, estimated glomerular filtration rate (eGFR, calculated using the CKD-EPI 
formula(21)), previous myocardial infarction, history of heart failure, peripheral artery 
disease, hypertension, diabetes mellitus, previous stroke, and medications (use of 
angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, statins and aspirin).  
These variables had a small proportion of missing values (<10%) and no multiple 
imputation was performed. We assessed interactions with the Log of time, age, sex, 
systolic blood pressure, and diabetes but none were significant (all p >0.10). 
Discrimination of the competing-risk regression model was assessed by 
calculating the C-statistics. Assessment of the calibration was performed by visually 
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plotting the cumulative incidence of observed versus expected stroke events derived 
from the competing risk model across sextiles of the predicted risk. Internal validation 
of the model was performed by bootstrapping (50x) and external validation was 
performed in the EPHESUS trial dataset. 
In order to create a simple integer risk score, continuous variables included in the 
chosen model, were categorized into either two or three groups using a combination of 
established clinical cut-points and graphical examination of rates across quintiles. To 
simplify the risk score, integer points were assigned to each prognostic factor based upon 
the log-hazard ratio estimates. The total risk score for each patient was calculated by 
summing the points across all chosen prognostic variables. From the overall distribution 
of the risk score we formed six categories of risk, containing approximately equal number 
of events. Within each risk category and by treatment group we calculated the number of 
events, person-years at risk, and the overall event rate. Kaplan–Meier plots were drawn 
showing the cumulative incidence curves by treatment group and risk category. 
All analysis was performed with STATA® software (version 14). A p-value 
<0.05 was considered as statistically significant. 
 
Results 
Population characteristics 
From the initial 28771 patients included in the high-risk MI pooled dataset(11), 
3754 were excluded from the analysis due to the presence and/or history of AF, and 
2113 patients were additionally excluded for being prescribed OAC leaving 22904 
patients included in the current analysis.  
The mean age was 64 (SD=11) years and 30% of patients were female. Patients 
who had a stroke during follow-up were older, more often female, smokers, and had 
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higher systolic blood pressure, were more often on Killip class 3 or 4, had lower eGFR, 
had higher proportion of previous MI events, HF history, hypertension, diabetes, and 
previous stroke. Table 1. 
During a median follow-up of 1.9 (percentile 25-75 1.3-2.7) years, 660 (2.9%) 
patients had a stroke. The stroke incidence rate was 4.1 (95%CI 3.9-4.5) per 1000 
patient-years. Table 1. 
Risk models 
The covariates retained in the final stroke risk model are depicted in Table 2. 
Older age, Killip class 3 or 4, eGFR ≤45 ml/min/1.73m2, hypertension history, and 
previous stroke were independently associated with increased risk of stroke.  
The models were well calibrated: a steep gradient in risk by sextiles of predicted 
risk was observed (Figure 1, Supplemental Table 1, and Figure 2), and showed 
moderate/good discrimination (c-index =0.67). The integer risk score derived from 
these covariates ranges from 0 to 11 points. Table 2.  
The model calibration remained good when patients with previous stroke were 
excluded from the analysis. Supplemental Table 2.  
The external validation was performed in the EPHESUS dataset also with good 
calibration and discrimination. Supplemental Table 3 & Table 3. 
Event rates  
 The 1, 2, and 3-year observed cumulative incidence rates of stroke were 1.3% 
(95%CI =1.2–1.4), 1.5% (95%CI =1.4–1.6), and 1.6% (95%CI =1.5–1.7), respectively.  
The observed 3-year stroke event rates increased steeply for each category of the 
risk score (1.8%, 2.9%, 4.1%, 5.6%, 8.3%, and 10.9%, respectively) and were in 
agreement with the expected event rates. Figure 1 and Supplemental Table 1.  
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An on-line calculator for stroke risk prediction in each individual patient (with 
the characteristics of those included in the present study) is available in the 
Supplemental Calculator. 
Event rates in patients with atrial fibrillation 
 Among the 3754 patients with AF at baseline, 215 (5.7%) had a stroke during a 
median follow-up of 1.7 (percentile 25-75 1.0-2.4) years.  The stroke incidence rate was 
9.5 (95%CI 8.3-10.8) per 1000 patient-years. The cumulative incidence at 1, 2, and 3 
years was 2.9% (95%CI =2.7–3.1), 3.3% (95%CI =3.0–3.6), and 3.4% (95%CI =3.1–
3.7), respectively.  
 
Discussion 
 Our study identifies readily available clinical risk factors associated with stroke 
in a population with MI complicated by systolic dysfunction and/or HF but without AF 
(or OAC treatment). These risk factors were computed in an easy-to-use risk score that 
provides useful prognostic information to clinicians and may serve to ascertain “risk 
enhancement strategies” in future trials for stroke prevention in populations with these 
characteristics. However, practical decisions regarding anti-coagulation in this 
population warrant prospective and randomized evidence before any such advice is 
provided.   
 Overall, post-MI patients with systolic dysfunction but without AF may have a 
higher risk of stroke than individuals without MI. However, this risk may still vary 
considerably among MI survivors, and be low (<2% at 3-years) for patients in the 
bottom sextile of our risk score or high (>10%) in patients with several risk factors (e.g., 
older age, impaired renal function, hypertension, previous stroke or Killip class 3/4) in 
the top sextile of the risk score.   
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 The overall stroke rate in our pooled data analysis overlapped that reported in 
other post-MI cohorts. In the Survival and Ventricular Enlargement trial(6) including 
2231 post-MI patients who had left ventricular systolic dysfunction and were followed 
for ≈42 months, 4.6% (n=103) had a stroke during the study (1.5% event rate per 
follow-up year). However, 16% of patients with stroke had AF vs. 10% of patients 
without stroke; p =0.03. Similarly, older age was also an independent risk factor for 
stroke. Reports derived from population-data show a ≈4% stroke incidence at 1-year 
post-MI and describe similar independent risk factors for stroke, such as age and 
previous stroke(5). A meta-analysis(22) reported lower rates of stroke in the post-MI 
setting (≈1-2%), but also found older age, hypertension and history of prior stroke (plus 
anterior MI, HF, diabetes, and AF) as independent risk factors for stroke. Although, 
these reports reinforce the external validity of our results, one should notice that the 
population included in our pooled dataset is a “high-risk” population i.e., all patients 
had MI complicated with systolic dysfunction and/or HF (or diabetes in the EPHESUS 
trial), hence is not surprising that we found higher stroke rates than those reported in 
“population-derived data”. However, when looking at patient-populations with similar 
characteristics (as in the Survival and Ventricular Enlargement trial) we find 
overlapping stroke rates (despite not having patients with AF in our cohort). Of note, 
although lower left ventricular ejection fraction has  been reported as a risk factor for 
stroke,(6) this that was not the case in our analysis. This may be due to the overall low 
ejection fraction of our patient-population, where an ejection fraction <35% was an 
entry criterion for these trials.  
In patients with AF the risk of stroke (and also the strategies to avoid stroke) are 
much better developed. Readily accessible risk scores are available for use in clinical 
practice. For instance the CHA2DS2-VASc [Congestive heart failure, Hypertension, Age 
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≥75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex 
category (female)](23) is recommended by the current guidelines and its use has been 
extensively validated(24, 25) (although the c-index of this score does not exceed 0.6 in 
most populations(23)). Notwithstanding, in daily practice most patients with AF and a 
CHA2DS2-VASc score of 1 or greater (according to the ESC guidelines) or ≥2 
(according to the AHA/ACC/HRS guidelines) should be treated with anticoagulant 
therapy (unless contra-indicated or counter balanced by a high bleeding risk)(24, 25). In 
our patient-population, the incidence rates for stroke in patients with AF were ≈2-fold 
higher compared to patients without AF. Patients without AF and with a risk score of 3 
or higher had similar (for stroke risk score =3) or higher (for stroke risk score >3) stroke 
rates. These data provide an idea of the magnitude of the problem. Patients without AF 
and with the characteristics depicted herein, that have a stroke risk score ≥3 may also 
benefit from oral anticoagulation as their AF counterparts.   
Despite observational data showing that some populations may also be at high 
risk for stroke despite not having AF(9), oral anticoagulation is not currently 
recommended as routine strategy for stroke prevention in patients without AF. A 
strategy of OAC was tested in patients with chronic HF in sinus rhythm (a different 
setting from that described herein) in the WARCEF trial(26). The rate of stroke was 
similar to that described in our report (≈1.4% at 3 years). As compared to aspirin 
warfarin did not reduce the primary composite outcome of ischemic stroke, intracerebral 
hemorrhage, or death from any cause. However, warfarin was associated with a lower 
rate of ischemic stroke (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; 
p =0.005) but increased the rate of major hemorrhage (1.78 events per 100 patient-years 
vs. 0.87; p <0.001), without differences in intracranial hemorrhage rates. 
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More recently, the COMPASS (Rivaroxaban with or without Aspirin in Stable 
Cardiovascular Disease) trial(27) evaluated whether rivaroxaban (2.5 mg twice daily) 
alone or in combination with aspirin (100 mg once daily) would be more effective than 
aspirin alone for secondary cardiovascular prevention in patients with stable 
atherosclerotic vascular disease. Approximatively 62 % and 22% of patients presented 
with a history of MI and HF at baseline, respectively. The primary outcome of CV 
death, stroke, or myocardial infarction occurred in fewer patients in the rivaroxaban-
plus-aspirin group than in the aspirin-alone group (4.1% vs 5.4%; HR =0.76; 95%CI 
=0.66-0.86; p <0.001), but major bleeding events occurred in more frequently in the 
rivaroxaban-plus-aspirin group, without difference in fatal or intracranial bleeding. It 
should be noted that the rate of ischemic stroke was lower in the rivaroxaban-plus-
aspirin and rivaroxaban alone groups compared to the aspirin-alone group, suggesting 
that low-dose rivaroxaban may prevent the occurrence of stroke even in the absence of 
AF.  
The COMMANDER-HF trial(28) is underway to assess whether rivaroxaban 
(2.5 mg twice daily) may prevent morbidity and mortality in patients with HF-REF plus 
coronary artery disease and without AF. The primary outcome is a composite of death, 
MI or stroke. The COMMANDER-HF trial may help to determine if low-dose 
rivaroxaban may prevent stroke in HF patients without AF. Downstream of COMPASS 
and COMMANDER-HF, whether the score we designed herein may further help 
identifying an even higher-stroke risk subgroup warrants a dedicated testing, along with 
the effect of antithrombotic strategies in this subgroup. 
A particular strength of this study is the validation of our predictive model in 
another data set. Consequently, our findings may have clinical implications - with a 
small number of 
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routinely collected clinical variables it is possible to identify patients with MI (plus 
systolic dysfunction and/or HF) but without AF who are at risk of stroke. Patients with a 
stroke risk score ≥3 have similar or higher stroke rates than patients with AF. To date 
there is no trial evidence to justify anticoagulant treatment in this population, but our 
findings may help in the identification of patients for such a trial. Of the five variables 
retained in our final stroke risk model, two variables were also found in HF-REF and 
HF-PEF populations(9, 29, 30) - older age and previous stroke, however lower eGFR, 
hypertension history and Killip class 3 or 4 are specific of MI patients with reduced left 
ventricular ejection fraction. 
 
Limitations 
 Several limitations should be acknowledged in this analysis. First, this is a non-
prespecified retrospective study of a pooled dataset from randomized clinical trials. 
Although the end-points have been independently adjudicated in each trial, no causality 
can be established and the associations reported herein are subject to the same potential 
bias of observational studies. Second, although an ECG was routinely performed at 
randomization we cannot ascertain which patients developed AF after randomization or 
even patients that had paroxysmal AF without being reported in the CRF. Hence many 
patients included in this analysis may actually have (or have developed AF). The fact 
that no time-interaction was observed may suggested that this did not have a substantial 
influence, as the risk factors present at short-time after MI did not vary significantly 
across follow-up. Third, the findings here reported cannot be generalized to other 
populations without these characteristics, particularly post-MI patients with preserved 
ejection fraction. Fourth, the type of stroke is not reported in the dataset. We assume 
that the great majority of strokes were ischemic but hemorrhagic strokes might also 
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have occurred(31).  Fifth, there are clinically relevant differences between the 
derivation cohort (EPHESUS trial) and the other cohorts (OPTIMAAL, CAPRICORN, 
and VALIANT trials). Differences as previous HF history (13% in EPHESUS vs. 44% 
in the other cohorts) and diabetes (32% in EPHESUS vs. 23% in the other cohorts) 
could have influenced the risk model discrimination. However, the discrimination 
ability of the developed stroke risk model is similar in validation and derivation cohorts 
(0.67 vs. 0.66). Sixth, patients without AF but treated on OACs were excluded from the 
present analysis that is tailored for MI populations with reduced ejection fraction and 
without AF or OACs treatment. Moreover, we could not ascertain the reasons for 
anticoagulation in this population, that could vary widely (e.g. pulmonary embolism, 
deep venous thrombosis, LV thrombus) and affect the validity of the stroke risk model. 
Lastly, the discrimination of the best stroke risk model developed herein was 
moderate/good (c-index≈0.7). A higher (>0.7) model discrimination would provide 
more accurate predictions in discriminating between patients with and without stroke. 
Nonetheless, a higher discrimination would not change clinical practice either. In order 
to change/guide patients` treatment adequately powered, randomized and controlled 
evidence is required. 
 
Conclusion 
 In a large population with MI complicated by systolic dysfunction or HF but 
without AF, readily accessible risk factors were identified and incorporated in an “easy-
to-use” risk score. This risk score may help in the identification of patients with a high 
stroke risk despite not having AF.  
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Clinical competencies and translational outlook 
We identified readily available risk factors for the occurrence of stroke in a 
population with myocardial infarction and left ventricular ejection fraction ≤35% 
without atrial fibrillation. The stroke risk score developed herein may help in the 
identification of patients with a high stroke risk (despite not having AF) and aid as 
“risk-enhancement” strategy for patient selection in future clinical trials targeting 
populations with the same characteristics of those described in the present study.  
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Figure 1. Model calibration plot: % of observed vs predicted events at 3-years by 
categories of stroke risk score. 
Legend: the models were well calibrated: a steep gradient in risk by sextiles of predicted 
risk was observed. 
 
 
Figure 2. Kaplan-Meier failure estimates curve by stroke risk score categories for the 
outcome of stroke with death as competing risk. 
Legend: stroke event rates increase by stroke risk score categories. 
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Table 1. Characteristics of the patients without atrial fibrillation and no oral anticoagulants 
Characteristics n 
No stroke 
(n=22244) 
Stroke 
(n=660) p-value 
Age, years 22904 64.1 ± 11.4 68.7 ± 10.0 <0.0001 
Female gender, n (%) 22904 6570 (29.5 %) 224 (33.9 %) 0.015 
BMI, Kg/m2 22368 27.5 ± 4.9 27.2 ± 4.2 0.064 
Current smoker, n (%) 22882 6730 (30.3 %) 244 (37.0 %) <0.0001 
SBP, mmHg 22863 121.8 ± 16.8 125.1 ± 18.6 <0.0001 
Heart rate, bpm 22850 75.3 ± 12.4 76.0 ± 13.4 0.15 
LVEF, % 15578 34.7 ± 8.8 34.4 ± 9.4 0.60 
Killip 3 or 4, n (%) 22819 3876 (17.5 %) 162 (24.6 %) <0.0001 
eGFR, ml/min/1.73m2 21974 71.3 ± 38.8 66.5 ± 31.9 0.002 
Hemoglobin, g/L 10298 133.7 ± 15.9 133.1 ± 14.6 0.55 
Sodium, mmol/L 10550 139.4 ± 3.8 139.1 ± 3.5 0.14 
Potassium, mmol/L 10497 4.3 ± 0.5 4.2 ± 0.5 0.16 
Previous MI, n (%) 22902 5537 (24.9 %) 207 (31.4 %) 0.0002 
CABG, n (%) 22904 1117 (5.0 %) 31 (4.7 %) 0.71 
PCI, n (%) 22904 4673 (21.0 %) 82 (12.4 %) <0.0001 
HF history, n (%) 22904 8215 (36.9 %) 270 (40.9 %) 0.037 
PAD, n (%) 22903 1694 (7.6 %) 63 (9.5 %) 0.066 
Hypertension, n (%) 22904 11890 (53.5 %) 407 (61.7 %) <0.0001 
Diabetes mellitus, n (%) 22904 5576 (25.1 %) 202 (30.6 %) 0.001 
COPD, n (%) 22904 1769 (8.0 %) 56 (8.5 %) 0.62 
Previous stroke, n (%) 22904 1522 (6.8 %) 115 (17.4 %) <0.0001 
Aspirin, n (%) 22904 19791 (89.0 %) 592 (89.7 %) 0.56 
ACEi/ARBs, n (%) 18283 9951 (55.8 %) 240 (52.1 %) 0.11 
Beta-blockers, n (%) 21282 13908 (67.4 %) 391 (61.7%) 0.003 
Diuretics, n (%) 22904 9415 (42.3 %) 323 (48.9 %) 0.0007 
Statins, n (%) 22904 7654 (34.4 %) 167 (25.3 %) <0.0001 
Stroke, n (%) 22904 0 (0.0 %) 660 (100.0 %) <0.0001 
ACM, n (%) 22904 3372 (15.2 %) 281 (42.6 %) <0.0001 
Legend: BMI, body mass index; SBP, systolic blood pressure; LVEF, left ventricular ejection 
fraction; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; CABG, 
coronary artery bypass grafting; PCI, percutaneous coronary intervention; HF, heart failure; 
PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; ACM, all-cause 
mortality. 
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Table 2. Multivariate competing risk model for Stroke 
Final model HR (95%CI) Coef. P-value Integer 
Age < 60 yr Ref. - -  
Age ≥60 to 75 1.82 (1.48-2.25) 0.60 <0.001 +2 
Age >75 2.12 (1.65-2.73) 0.75 <0.001 +3 
Killip class 3 or 4 1.31 (1.09-1.57) 0.27 0.004 +1 
eGFR >60 ml/min/1.73m2 Ref. - -  
eGFR >45 to 60 0.91 (0.74-1.11) -0.09 0.37 - 
eGFR ≥30 to ≤45 1.29 (1.02-1.63) 0.26 0.031 +1 
Hypertension  1.18 (1.00-1.40) 0.17 0.045 +1 
Previous stroke 2.21 (1.78-2.74) 0.80 <0.001 +3 
Model C-index (Harrell`s C) =0.67 
Final report after 50x bootstrap. 
Legend: eGFR, estimated glomerular filtration rate. 
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Table 3. External validation of the risk model in the EPHESUS dataset  
Stroke risk score 
(6 categories) 
n. (%) n. events % observed % expected 
0 or 1 1,789 (35.5)  17 1.5 1.8 
2 689 (13.7) 14 3.7 3.0 
3 1,217 (24.2) 31 3.8 3.6 
4 734 (14.6) 24 4.2 4.1 
5 277 (5.5)  12 6.7 5.0 
≥6 332 (6.6) 12 7.0 8.2 
C-index of the stroke risk model in the EPHESUS dataset =0.66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
